At the time of writing, MBX Biosciences Inc [MBX] stock is trading at $17.44, up 2.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MBX shares have gain 22.56% over the last week, with a monthly amount drifted -0.40%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MBX Biosciences Inc [NASDAQ: MBX] stock has seen the most recent analyst activity on October 15, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $50. On August 05, 2025, Mizuho initiated with a Outperform rating and assigned a price target of $38 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $38 on July 16, 2025. Citizens JMP initiated its recommendation with a Mkt Outperform and recommended $38 as its price target on April 10, 2025. Stifel started tracking with a Buy rating for this stock on October 08, 2024, and assigned it a price target of $40. In a note dated October 08, 2024, JP Morgan initiated an Overweight rating and provided a target price of $30 on this stock.
For the past year, the stock price of MBX Biosciences Inc fluctuated between $4.81 and $27.50. Currently, Wall Street analysts expect the stock to reach $38 within the next 12 months. MBX Biosciences Inc [NASDAQ: MBX] shares were valued at $17.44 at the most recent close of the market. An investor can expect a potential return of 117.89% based on the average MBX price forecast.
Analyzing the MBX fundamentals
Gross Profit Margin for this corporation currently stands at -0.75% with Operating Profit Margin at -389.89%, Pretax Profit Margin comes in at -346.93%, and Net Profit Margin reading is -346.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.31 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.97 points at the first support level, and at 16.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.86, and for the 2nd resistance point, it is at 18.28.
Ratios To Look Out For
It is important to note that MBX Biosciences Inc [NASDAQ:MBX] has a current ratio of 19.50. Further, the Quick Ratio stands at 19.50, while the Cash Ratio is 3.38.
Transactions by insiders
Recent insider trading involved Hawryluk P. Kent, President & CEO, that happened on Oct 20 ’25 when 20000.0 shares were purchased. Director, Hoerter Steven L. completed a deal on Oct 17 ’25 to buy 20000.0 shares. Meanwhile, Director Heron Patrick J bought 0.67 million shares on Sep 26 ’25.
